Industries > Pharma > Outsourcing Regulatory Market Affairs Report 2019-2029
Outsourcing Regulatory Market Affairs Report 2019-2029
Analysis by Service (Regulatory consulting, Legal representation, Regulatory writing and publishing, Product registration and Clinical Trial Application, Other Regulatory Service), and by Region (North America, Europe, Asia Pacific, Latin America, MEA), Company and Country Analysis and Forecasts
Market Definition:
• Sometimes the company own in-house workforce support is not ample to handle company expansion. To maintain that swiftness the company hires a skilled workforce from a third party firm, to set up them as per the company needs without hampering its current business. This process is known as outsourcing.
• Outsourcing can free up facilities and time resources which results in lower energy costs, taxes and reduction in production cost. Companies apply outsourcing strategies not only for cost saving but also to focus on its core business competencies.
• Regulatory affairs which is also known as government affairs, is a profession developed from the desire of governments to protect public health by managing the efficacy and safety of products in areas including veterinary medicines, pharmaceuticals, pesticides, agrochemicals, medical devices, complementary medicines and cosmetics, etc.
Market Overview and Trends
• The outsourcing of regulatory market affairs is on the rise. Outsourcing Regulatory Affairs activities to the Contract Research Organisations (CROs) offers cost efficiency, reduced regulatory submission time, and quality control in the overall manufacturing process. These factors are expected to give a rise to the outsourcing regulatory market.
• Regulatory Affairs Outsourcing market by manufacturer’s data helps the user to be familiar with the competitors. Manufacturer covers data including shipment, price, revenue, gross profit, interview record, business distribution and others. Regulatory Affairs Outsourcing market by manufacturer’s data helps the user to be familiar with the competitors. Manufacturer covers data including shipment, price, revenue, gross profit, interview record, business distribution and others.
• A major advantage of outsourcing is that companies can focus on their most important marketing authorisations and procedures such as product development processes which also are a reason for the growth of outsourcing regulatory market.
Market Dynamics:
Factors Influencing the Market Growth:
• The growth of the market is expected to increase by rise in R&D activities, especially in life science industry for the depletion in overall approval process by reducing delays in regulatory filings and the improvement in the Return on Investment (ROI) and cost efficiency.
• Outsourcing regulatory affairs activities exercises to the contract research organisations (CROs) propose cost efficiency; reduce regulatory submission time, and quality control in the manufacturing procedure. These elements drive the development of the market.
• Food and Drug Administration (FDA) has developed few digital programs such as a model for the digital health pre-certification program, policies for the multi-functional medical devices and internal data science incubator. The purpose of such initiatives is to utilise the potential of digital health tools in regulatory affairs to decrease the growing healthcare costs and patient risks.
Factors Restraining the Market Growth:
• The factors restraining the Outsourcing regulatory affairs market growth are Monitoring issues & lack of standardisation and Risk associated with data security.
Market Segmentation 2019-2029:
The Outsourcing regulatory affairs market is segmented on the service and region.
1. Outsourcing regulatory affairs, by Service
a) Regulatory consulting
b) Legal representation
c) Regulatory writing and publishing
d) Product registration and clinical trial application
e) Other regulatory service
2. Outsourcing regulatory affairs, by Region
a) North America
– US
– Canada
b) Europe
– Germany
– UK
– France
– Rest of Europe
c) Asia Pacific
– Japan
– China
– India
– Rest of Asia Pacific
d) Rest of the World (RoW)
Competitive Analysis:
• Research and development is the primary strategy adopted by the key players in the Global Biodefense market.
• These companies have developed various strategies and developments such as product launch, partnerships, mergers & acquisitions, joint venture, and collaborations.
Major Market Players:
PAREXEL International Corporation, IQVIA Holdings, Inc., Charles River Laboratories International, Inc., ICON plc, Covance, Inc., Genpact Limited, Intertek Group plc, Medpace, Inc., PRA Health Sciences, Inc., Syneos Health, Inc., Accell Clinical Research, LLC and other players.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Download sample pages
Complete the form below to download your free sample pages for Outsourcing Regulatory Market Affairs Report 2019-2029Download sample pages
Complete the form below to download your free sample pages for Outsourcing Regulatory Market Affairs Report 2019-2029
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034
The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.
23 April 2024
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
